BioAge Labs Raises $132.3M and Reports 86% BGE-102 Phase 1 hsCRP Reduction
BioAge Labs reported an 86% reduction in hsCRP, 58% drop in IL-6 and 30% decrease in fibrinogen in its Phase 1 BGE-102 trial, supporting once-daily dosing and a Phase 2a cardiovascular risk study in 1H 2026. The company raised $132.3 million in a follow-on offering, extending cash runway through 2029.
1. Phase 1 Interim Data
BioAge Labs reported positive Phase 1 results for BGE-102, its oral brain-penetrant NLRP3 inhibitor, demonstrating well-tolerated single and multiple ascending doses with 86% hsCRP suppression, 58% IL-6 reduction and 30% fibrinogen decrease at 120 mg daily, plus CSF concentrations exceeding IC90 at doses ≥60 mg. These findings underpin a planned Phase 2a proof-of-concept cardiovascular risk trial set to begin in the first half of 2026.
2. Ophthalmology Expansion
The company expanded BGE-102 into ophthalmology after preclinical studies showed dose-dependent retinal vascular protection and near-complete prevention of leakage. A Phase 1b/2a proof-of-concept trial in diabetic macular edema patients is scheduled to start in mid-2026, with results expected by mid-2027.
3. Financial Strengthening
In January 2026 BioAge completed a follow-on public offering of 5.9 million shares at $19.50, with full exercise of the underwriters’ option in February raising total gross proceeds of $132.3 million. Combined with $285.1 million in cash and equivalents as of December 31, 2025, the financing is projected to fund operations through 2029.